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To eliminate lymphatic filariasis (LF) by 2020, the World Health Organization (WHO) has launched a campaign
against the disease. Since the launch in 2000, significant progress has been made to achieve this ambitious
goal. In this article we review the progress and status of the LF programme in Africa through theWHO neglected
tropical diseases preventive chemotherapy databank, the Expanded Special Project for Elimination of Neglected
Tropical Diseases (ESPEN) portal and other publications. In the African Region there are 35 countries endemic
for LF. The Gambia was reclassified as not requiring preventive chemotherapy in 2015, while Togo and Malawi
eliminated LF as a public health problem in 2017 and 2020, respectively. Cameroon discontinued mass drug
administration (MDA) and transitioned to post-MDA surveillance to validate elimination. The trajectory of cover-
age continues to accelerate; treatment coverage increased from 0.1% in 2000 to 62.1% in 2018. Geographical
coverage has also significantly increased, from 62.7% in 2015 to 78.5% in 2018. In 2019, 23 of 31 countries re-
quiring MDA achieved 100% geographic coverage. Although much remains to be done, morbidity management
and disability prevention services have steadily increased in recent years. Vector control interventions conducted
by other programmes, particularly malaria vector control, have had a profound effect in stopping transmission
in some endemic countries in the region. In conclusion, significant progress has beenmade in the LF programme
in the region while we identify the key remaining challenges in achieving an Africa free of LF.
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Introduction
In the past 20 y, momentum to eliminate lymphatic filaria-
sis (LF) in Africa has significantly improved as a result of de-
velopment of single-dose treatment strategies, point-of-care
diagnostic tools, generous donations of medicines from phar-
maceutical companies and financial support for programme im-
plementation from the donor community.1 The African Region
(AFRO) of the World Health Organization (WHO) includes 38.3%
of the global population and 31 of the 49 countries requiring pre-
ventive chemotherapy for LF, a debilitating vector-borne infec-
tion that affects the poorest populations.2 In Africa it is caused
byWuchereria bancrofti and is mainly transmitted to humans by
mosquito species belonging to Anopheles and Culex.3 In 2000
there were 39 countries believed to be endemic for LF in theWHO
AFRO. By that same year, 405.9 million people in 39 countries in
Africa were estimated to require preventive chemotherapy. How-
ever, according to progress report of the Global Programme to
Eliminate Lymphatic Filariasis for 2000–2009,4 the evidence for
active transmission of LF in many of the 39 endemic countries
was weak and some probably did not require mass drug admin-
istration (MDA). The status of five countries (Burundi, Cape Verde,
Mauritius, Rwanda and Seychelles) were reviewed in 2011 and
were reclassified as non-endemic, reducing the number of en-
demic countries in Africa to 34 (inclusion of South Sudan following
independence in 2011 now makes 35).5 Of the 35 LF-endemic
countries in the region, 2 have eliminated LF as a public health
problem (Malawi and Togo), The Gambia was reclassified as not
requiring preventive chemotherapy and Cameroon is under post-
MDA surveillance to validate if elimination targets have been
achieved. In the remaining 31 countries there remain 341.4
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Table 1. Lymphatic filariasis implementation status in the WHO AFRO as of January 2020
Indicator Number of countries
Countries verified as eliminating LF as a public health problem 2: Malawi and Togo2,6
Countries stopped MDA (under surveillance) 1: Cameroon2
Countries implementing MDA with 100% geographical coverage 23: Benin, Burkina Faso, Chad, Comoros, Congo, Côte d’Ivoire,
Eritrea, Ethiopia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia,
Mali, Mozambique, Niger, Senegal, Sao Tome and Principe, Sierra
Leone, Uganda, United Republic of Tanzania, Zambia and
Zimbabwe6
Countries implementing MDA in only part of the geographical area
considered in need of treatment
6: Angola, Central African Republic, Democratic Republic of the
Congo, Madagascar, Nigeria and South Sudan6
Countries reclassified as not requiring preventive chemotherapy 1: The Gambia7
Countries where MDA is not yet started 2: Equatorial Guinea and Gabon2
Countries with mapping gap 1: Equatorial Guinea6
million people who require preventive chemotherapy for LF2
(Table 1).
Progress and achievements
Mapping the geographical distribution of LF
Mapping the geographical distribution of a disease is a key step
prior to the implementation of any public health intervention. In
2000, the first LF mapping was initiated in Africa and by 2001,
four countries had already completed mapping (Benin, Burkina
Faso, Ghana and Togo).8 Mapping was subsequently conducted
in the remaining countries within the region from 2002 to 2012
with the support of different stakeholders and from 2013 to 2015
under the leadership of theWHOAFROMapping Project. The AFRO
Mapping Project accelerated themapping of LF inmany countries.
Nevertheless, mapping was delayed in three countries (Central
African Republic, Mauritania and South Sudan) due to security-
related challenges. It was only in 2018 and 2019 that these coun-
tries were able to complete LF mapping under the leadership
of the WHO Expanded Special Project for the Elimination of Ne-
glected Tropical Diseases (ESPEN). Currently only one implemen-
tation unit (Annanbon) in Equatorial Guinea is unmapped be-
cause of its inaccessibility.
MDA
MDA with albendazole in combination with either ivermectin or
diethylcarbamazine (the latter combination in countries non-
co-endemic for onchocerciasis) or albendazole alone were im-
plemented progressively in endemic counties. In 2000, the
AFRO treated only 363607 people compared with 212.7 mil-
lion in 2018, according to data from the WHO neglected
tropical diseases preventive chemotherapy (PCT) databank9
(Figure 1).10,11 By the beginning of 2020, a total of 23 of
31 countries had implemented at least one round of MDA in
all endemic implementation units (IUs).11 Only two countries
(Equatorial Guinea andGabon) have yet to commenceMDA.11 The
trajectory of coverage continues to increase, from 0.1% in 2000
to 62.1% in 2018. Similarly, the proportion of countries that have
achieved national effective coverage (defined as coverage of at
least 65% for LF) has increased from 68.1% in 2015 to 90.2% in
2018.7,11 The proportion of IUs delivering preventive chemother-
apy in IUs requiringMDA reached 78.5% in 2018, up from62.7% in
2015.7,11 The LF programme is one the biggest deworming pro-
grammes in Africa. Since all LF-endemic countries are also en-
demic for soil-transmitted helminthiasis (STH), many school-age
children have benefited through the LF programme, although the
impact has yet to be quantified.12
Triple therapy
The treatment, known as triple therapy, involves a combination
of ivermectin, diethylcarbamazine citrate and albendazole (IDA)
in areas where onchocerciasis is not endemic.13 Studies have
demonstrated that IDA is superior to the previous standard reg-
imens of diethylcarbamazine plus albendazole (two-drug regi-
men),14,15 as IDA clears microfilaria more efficiently from the
blood than the two-drug regimen and is equally safe.14,16 In
2017 the WHO released a new guideline recommending the IDA
regimen as an alternative treatment strategy in certain settings
where onchocerciasis is not endemic.13 In May 2018 in Nairobi,
the WHO convened a technical meeting on IDA in Africa to re-
view the progress of seven countries eligible for IDA for the elim-
ination of LF and to guide the implementation of the strategy.
Kenya was the first country in the region to implement the strat-
egy in three subcounties targeting 278291 individuals.2 A year
later, São Tomé and Príncipe treated 148460 of 206194 individ-
uals with the triple-drug regimen, reaching national coverage of
72%. All the treated IUs achieved effective coverage. Building on
that success, Comoros, Eritrea andMadagascar have planned the
implementation of IDA in 2020. With more than four rounds of
MDA with the double therapy, Zambia was not found to be eli-
gible for IDA, while Zimbabwe, with two rounds of MDA, will re-
evaluate its situation in 2020 before deciding if IDA should be
implemented.
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Figure 1. Number of people treated and progress in preventive chemotherapy coverage, 2000–2018. Data for this figure were accessed from the
neglected tropical diseases PCT databank.9
Transmission assessment survey (TAS)
A TAS is recommended in an evaluation unit (EU) after a suc-
cessful preliminary survey (pre-TAS) to determinewhen infections
have been reduced below target thresholds (interruption of trans-
mission) and MDA can stop after at least five consecutive rounds
with effective coverage. It is recommended to conduct three TASs
with an interval of 2 y between each. As of December 2019, a TAS
had been conducted in 370 EUs covering 1533 IUs in 16 countries.
In total, TAS1 has been implemented in 749 IUs, TAS2 in 581 IUs
and TAS3 in 203 IUs representing 31.6%, 24.5%and8.6%, respec-
tively, of the 2372 endemic IUs, with the technical and financial
support of either the WHO or other partners.
Morbidity management and disability prevention
Morbidity alleviation, the second pillar of the global program, was
almost non-existent in 2000. By 2015, 11 endemic countrieswere
reporting hydrocele and lymphedema patients, while 12 coun-
tries reported on morbidity management and disability preven-
tion (MMDP) services. There has been steady progress over the
years, with 22 and 23 countries reporting on lymphedema and
hydrocele cases, respectively, as of the beginning of 2019. A study
in Malawi documented that hydrocele surgery improves quality
of life significantly at 6 months post-surgery.17 Another study
showed that the lifetime benefits of hydrocelectomy by far ex-
ceed the costs of repairing hydroceles.18 MMDP activities have
generally lagged behind MDA and there is a need to improve the
coverage of MMDP services and the number of countries imple-
menting these patient-oriented morbidity interventions.
Vector control
The WHO Position Statement on Integrated Vector Management
(IVM) recommends integrated vector control of malaria and LF.19
These recommendations are pertinent in Africa because Anophe-
les species are the common vectors of both infections and vector
control interventions, particularly insecticide-treated mosquito
nets (ITNs) and indoor residual spraying, impact the transmis-
sion of both Plasmodium and Wuchereria, shown initially in the
Solomon Islands.20,21 Studies have documented that the preva-
lence of W. bancrofti infection in The Gambia was among the
highest in Africa in the 1950s.22,23 Nonetheless, different surveys
conducted in 1975 and 1976 revealed a significant decline in en-
demicity in the absence of MDA.24 A study conducted in 2013,
using the TASmethodology, confirmed the transmission interrup-
tion of W. bancrofti in The Gambia.25 The studies attributed the
decline in prevalence to a significant reduction in mosquito den-
sity through the widespread use of ITNs as part of the national
malaria control programme, which is in accordance with the re-
sults of a study conducted in Zambia.26
Another study highlighted the role of competitive exclusion in
the low endemicity of LF in Central Africa.27 In ecology, compet-
itive exclusion states that two species competing for the same
resources cannot stably coexist when all other ecological factors
are constant. When one species has even the slightest advan-
tage over the other, then one will dominate in the long term or
one of the competitors will adapt via a behavioural shift towards
a different ecological niche.27 Six filarial parasites can infect peo-
ple in sub-Saharan Africa:W. bancrofti, Onchocerca volvulus, Loa
loa,Mansonella perstans,Mansonella streptocerca and Dracuncu-
lus medinensis. Although there is some degree of co-endemicity
among these filarial parasites, there are also areas where com-
petitive exclusion is proposed to reduce this co-endemicity, which
reduces the likelihood of competition for resources given the dis-
tribution of adult and microfilaria larvae into separate niches in
the human host through spatial and temporal segregation, as
shown by the different niches of adult filariae and the differ-
ent periodicities of the microfilariae or sites (peripheral blood or
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Figure 2. Status of LF programme implementation in Africa. Data for developing the maps were accessed from the ESPEN portal.28
skin) while the vectors of African filariae are from different insect
groups (mosquitoes, Chrysops, Simulium and Culicoides) with dif-
ferent biting habits.25
Elimination of LF as a public health problem
Two countries, Togo and Malawi, from the WHO AFRO eliminated
LF as a public health problem in 2017 and 2020, respectively.
In 2019, Cameroon discontinued MDA programmes and transi-
tioned to post-elimination surveillance. Several countries (Benin,
Burkina Faso, Ethiopia, Ghana, Madagascar, Mali, Nigeria, Sene-
gal, Uganda and the United Republic of Tanzania) have stopped
MDA in at least one EU based on data from the ESPEN portal.28
(Figure 2)
Programme challenges
Despite these achievements in the AFRO, several challenges have
been encountered, including security problems reducing access
and political instability in some countries, that has contributed
to delayed mapping of LF and the conducting of TASs. For in-
stance, Central African Republic, Mauritania and South Sudan
completed their mapping in 2018 and 2019. Another challenge
to be highlighted is the co-endemicity with L. loa in most of the
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countries in Central Africa, which has contributed to delays in the
implementation of MDA in some countries until the WHO recom-
mended biannual MDA with albendazole in LF–Loa co-endemic
settings.13,27,29 Implementation of an ivermectin-based commu-
nity treatment strategy for the elimination of LF has been delayed
in Central Africa because of the occurrence of serious adverse
events, including post-ivermectin encephalopathy and death, in
persons with high levels of circulating L. loa microfilariae.30–32 L.
loa cross-reactivity continued to be a challenge for mapping LF
in Central Africa. Studies have documented that antigen-based
tests such as the Filariasis Test Strip (FTS)33,34 provide false-
positive results in areas where L. loa is highly prevalent, indicating
theneed for developing a confirmatorymapping strategy for such
scenarios.35
MDA is designed for rural populations and poses significant
challenges when it is implemented in urban areas due to pop-
ulation density, population mobility and challenges on how
to define target areas for implementation of the strategy.36,37
Re-evaluation of MDA is recommended given the challenge of
achieving effective coverage of MDA in such settings.36 While on-
going transmission ofW. bancrofti in cities in East Africa36 is possi-
ble, in West Africa, transmission might not be ongoing due to the
fact that Culex sp. mosquitoes are inefficient vectors of W. ban-
crofti in West Africa.38,39 Prevalences of <1% were registered in
many of the cities, including Monrovia, Freetown, Conakry and ur-
ban areas in Kano State in Nigeria.37,40,41 Therefore re-evaluation
of the current endemicity status of the urban areas inWest Africa
is important.
Much of the focus of the LF elimination programme has been
on MDA and there had been little progress in the implementation
of the second pillar, morbidity management and disability pre-
vention. It is only in recent years that countries are focusing em-
phasis on this necessary intervention and scaling up the services
for those in need. The increasing level of resistance to present
pyrethroid-based insecticides is another challenge to the vector
control aspect of the programme.42
LF elimination prospects for 2030
The new Neglected Tropical Diseases Roadmap targets valida-
tion by 2030 of elimination of LF as a public health problem from
81% of the endemic countries globally.43 In the AFRO, building
on the lessons learned in LF elimination from Malawi and Togo,
endemic countries in the region should use the opportunity to
defeat LF once and for all. Lessons learned from Togo demon-
strated that strong political commitment, integration with exist-
ing health interventions, innovative resources mobilization and
very strong partnerships were success factors.44 The country se-
cured joint malaria/LF funding with grants from the Global Fund
to Fight AIDS, Tuberculosis and Malaria (GFATM), which facilitated
the implementation of a joint programme for the two diseases.44
Conclusions
Over the past 20 y significant progress has been achieved in
the AFRO of the WHO as a result of innovation in treatment
and diagnostics, the provision of donated medicines and finan-
cial support and strong partnerships allied with greater country
commitments. Several key milestones have been achieved: map-
ping has almost been completed; MDA has been scaled up in al-
most all countries, with the majority of the countries reaching
100% geographical coverage, to accelerate elimination and IDA
MDA has been started in the region. Most importantly, two coun-
tries have eliminated LF as a public health problem in the region.
Despite this significant progress, there are remaining challenges
that need to be addressed to see Africa free of LF.
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